Immune checkpoint therapy has demonstrated great promise by providing durable responses for a subset of patients with difficult-to-treat tumors like melanoma and non-small cell lung cancer. The challenge ahead is to extend these benefits to greater numbers of patients with additional disease types. A wide range of novel targets and treatment modalities is being evaluated to meet this need.
This talk focuses on available preclinical models and their use in the discovery and characterization of new treatments and combinations intended to augment the anti-tumor immune response.
- Eddie Wood, PhD, Research Director, Charles River